Deferiprone: pan-European multi-centre study

neurones firing copyDr David Devos is leading Europe-wide consortia of neurologists and Parkinson’s specialists to secure funding from the EU’s Horizon 2020 programme to run a clinical trial through 28 centres across Europe to understand the efficacy of Deferiprone, an iron-chelator in the treatment of people with Parkinson’s. ‘The Cure Parkinson’s Trust is supporting this important trial as Deferiprone was prioritised in 2012 by our Linked Clinical Trials Committee, so seeing this potentially valuable treatment come forward into trial is wonderful.’ says Dr Richard Wyse.

Sixty patients within the study will also be asked to use the SENSE-PARK objective measurement system, which The Cure Parkinson’s Trust helped to develop between 2011 and 2014.

There will be three centres within the UK, and recruitment has now started. Further information about the study can be found on the trial website and more details on specific recruitment centres can be found here.

 

RELATED ITEMS

  • Trials using treatments to slow, stop or reverse Parkinson’s The Cure Parkinson's Trust manage and facilitate an innovative research programme called Linked Clinical Trials with the sole aim of bringing forward treatments that biochemically show the potential to slow, stop or reverse Parkinson's. Each year around 25 compounds are evaluated…
  • At our patient advocate Rallying to the Challenge Meeting in 2014 it was unanimously agreed in the value of developing a clinical trials charter to significantly improve communication between those taking part in trials and those running clinical trials. The Charter was developed by people living with Parkinson's and clinicians…
  • Recruitment for this study, to explore whether simvastatin may be an effective treatment for Parkinson’s is now underway. The study is being directed by Plymouth University Peninsula Schools of Medicine and Dentistry (PUPSMD), and has been supported by the JP Moulton Trust and The Cure Parkinson’s Trust. For further details please…
  • A new study, part of The Cure Parkinson's Trust's Linked Clinical Trials Programme, is starting at University College London Hospital (UCLH). The study is researching a new possible treatment, EPI-589, to explore whether it is well tolerated and could improve the biochemical profile in Parkinson’s patients. The study will involve three months…
  • The quiet revolution I think we all accept the notion that clinical trials are central to the development of new medicines and new treatments for Parkinson's. And it's also true that the majority of these will be conducted by the pharmaceutical industry or academic units. Both have a strong vested…